Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CARM1 | Q86X55 | 5/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.33 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.30 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23568463 | 0.82 | L3MBTL1 (0.44) | L3MBTL1CARM1PRMT6KCNH2CACNA1I | |
| SCHEMBL23588513 | 0.81 | SAT1 (0.39) | CARM1PRMT6KCNH2CACNA1ICXCR4 | |
| SCHEMBL19476277 | 0.81 | KCNH2 (0.35) | CARM1PRMT6KCNH2CACNA1I | |
| SCHEMBL17010888 | 0.80 | CACNA1I (0.40) | KCNH2CACNA1I | |
| SCHEMBL8427954 | 0.78 | SLC18A3 (0.34) | KCNH2CACNA1I | |
| SCHEMBL12605183 | 0.75 | L3MBTL1 (0.47) | L3MBTL1CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL8246654 | 0.74 | SLC6A3 (0.33) | — | |
| SCHEMBL14393411 | 0.74 | HRH3 (0.37) | KCNH2CACNA1IGNAO1 | |
| SCHEMBL19010251 | 0.74 | EPHX1 (0.40) | CARM1PRMT6KCNH2CACNA1I | |
| SCHEMBL16748042 | 0.74 | L3MBTL1 (0.46) | L3MBTL1CARM1PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | Epizyme, Inc. | 2017-12-14 | — | — | US | disclosed |
| US-9108953-B2 | Quinoline derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355712-A1 | AMINE-SUBSTITUTED ARYL OR HETEROARYL COMPOUNDS | SHMT1, BHMT, BHMT2 | L3MBTL1 969/4885CARM1 24/4885PRMT6 36/4885 |
| US-20150148344-A1 | QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD7, BRD3 | L3MBTL1 1104/4885CARM1 366/4885PRMT6 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.